...
首页> 外文期刊>Asian spine journal. >Effect of Teriparatide on Subsequent Vertebral Fractures after Instrumented Fusion Surgery for Osteoporotic Vertebral Fractures with Neurological Deficits
【24h】

Effect of Teriparatide on Subsequent Vertebral Fractures after Instrumented Fusion Surgery for Osteoporotic Vertebral Fractures with Neurological Deficits

机译:Triparatide对骨质疏松椎骨骨折仪器融合手术后随后椎骨骨折的影响

获取原文
           

摘要

Study Design Retrospective case review. Purpose To assess the incidence and effect of teriparatide (TP) on subsequent vertebral fractures following a long-instrumented fusion surgery for osteoporotic vertebral fractures (OVFs). Overview of Literature TP treatment may be a useful strategy for patients with OVFs treated with a long-instrumented surgery. Methods Overall, 47 patients who underwent long-instrumented fusion surgery (≥3 levels) for OVFs with neurological deficits between 2010 and 2013 were enrolled. The mean age of the subjects was 76 years; the study population comprised 20 males and 27 females. The mean follow-up duration was 23 months. The average of fused vertebrae was 4.9. TP was used for 19 patients who comprised the TP group. The incidence of subsequent VFs was estimated with Kaplan–Meier analyses and compared between the TP and non-TP groups using the log-rank test. Risk factors were evaluated using a Cox proportional hazards model. Results A total of 38% (18/47 cases) of the subjects were identified with subsequent VFs. There were no significant differences in the age, sex, fused levels, presence of prevalent fractures, and correction loss of the two groups. The occurrence of subsequent VFs was lower in the TP group than in the non-TP group (16% vs. 54%, p =0.014). The log-rank test revealed that the TP treatment significantly reduced the risk of subsequent VFs ( p =0.048). A Cox proportional hazards model revealed that preoperative TP treatment is only a protective factor of subsequent VFs after instrumented fusion surgery for OVFs (hazard ratio, 0.281; p =0.047). Conclusions In this retrospective study, pre- and postoperative TP treatment significantly reduced the incidence of subsequent VFs after instrumented fusion surgery for OVFs. A prospective randomized study is warranted to determine the efficacy of TP treatments.
机译:研究设计回顾性案例审查。目的在骨质疏松椎骨骨折(OVF)的长仪剂融合手术后,评估Teriparatide(TP)对随后的椎骨骨折的发病率和影响。文学TP治疗概述可能是患有长型手术治疗的OVF患者的有用策略。方法总体而言,47名患者在2010年至2013年间,ovfs接受过型融合手术(≥3级)的卵型融合手术(≥3水平)。受试者的平均年龄为76岁;研究人口包含20名男性和27名女性。平均随访时间为23个月。熔融椎骨的平均值为4.9。 TP用于19名由TP组组成的患者。随后的VFS的发病率估计了Kaplan-Meier分析,并使用日志秩检验比较TP和非TP组。使用COX比例危险模型评估风险因素。结果总共38%(18/47例)的受试者鉴定了随后的VFS。年龄,性别,融合水平,普遍性骨折的存在和两组的矫正损失没有显着差异。在TP组中发生后续VF的发生比非TP组(16%对54%,P = 0.014)。对数秩测试显示TP处理显着降低了随后的VF的风险(p = 0.048)。 Cox比例危害模型显示,术前TP治疗仅是ovfs(危险比,0.281; p = 0.047)仪器融合手术后随后的VFS的保护因子。结论在这种回顾性研究中,预先和术后TP治疗显着降低了OVF型融合手术后随后的VFS的发生率。需要预期随机研究,以确定TP治疗的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号